PROVISION OF HISTOPATHOLOGY SERVICES

Description

PROVISION OF DIGITAL HISTOLOGY EXTERNAL REPORTING <br/>SERVICES FOR AIREDALE AND BRADFORD Lot 1: PROVISION OF DIGITAL HISTOPATHOLOGY SERVICES FOR AIREDALE AND BRADFORD, DIAGNOSTIC HISTOLOGY REPORTING SERVICE VIA SLIDE OR DIGITAL IMAGE TO BE DELIVERED AS AND WHEN REQUIRED BY THE CONTRACTING AUTHORITY. THE CONTRACT VALUE IS ESTIMATED AND WILL VARY BASED ON ACTIVITY LEVELS. THE INITIAL CONTRACT TERM WILL RUN FROM 01/06/2026 TO 30/06/2027.<br/><br/>THIS CONTRACT HAS NOT YET FORMALLY BEEN AWARDED; THIS NOTICE IS FOR PRIOR INFORMATION ONLY AND THE CONTRACT WILL NOT BE AWARDED UNTIL THE STANDSTILL PERIOD HAS ENDED AND ANY REPRESENTATIONS HAVE BEEN CONSIDERED.<br/><br/>NO CONFLICTS OF INTEREST WERE IDENTIFIED DURING THE PROCUREMENT PROCESS.<br/><br/>NO SUBCONTRACTING IS EXPECTED. Additional information: This is a Provider Selection Regime (PSR) intended approach notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.’<br/><br/>Award decision-makers;<br/>Sarah Walters<br/>Mark Harrison<br/><br/>Based on the Authorities assessment and PSR decision making process (taking into account key criteria; quality, value, integration, inequalities and access), ILS LLP intends to award a contract following MSP Process under the Provider Selection Regime (PSR).<br/><br/>The authority is proposing a new contract to replace the existing contract at the end of its term and the proposed contracting arrangements are not changing considerably.<br/><br/>ILS LLP is of the view that they are able to identify the most suitable provider without running a competitive exercise.<br/><br/>Direct Award Processes A (only one provider can provide the services) and B (unrestricted patient choice) and C where an existing provider is satisfying its contract and the new contract will not be materially different from the current contract do not apply and a competitive process is unlikely to add value for patients, taxpayers, or the population.